Microbiotica, a pioneering company in the field of microbiome analysis, has successfully raised $50 million in its latest funding round. Originally formed through a decade-long investment in the Wellcome Sanger Institute, Microbiotica has harnessed its unparalleled capabilities in gut bacterial culturing, establishing itself as a global frontrunner in microbiome research. The company possesses an extensive microbiome Culture Collection, a proprietary Reference Genome Database, and advanced bioinformatics expertise, enabling them to link complex microbiome data to patient phenotypes in unprecedented ways. This recent funding will bolster Microbiotica's efforts to advance their pipeline of clinically-derived products, which includes innovative Live Bacterial Therapeutics and Biomarkers targeting key areas such as Inflammatory Bowel Disease (IBD), Immuno-oncology, and Gut Epithelial Barrier Repair. The infusion of capital will also facilitate further collaborations with prestigious institutions like Cancer Research UK and Cambridge University Hospitals in Immuno-oncology, as well as partnerships with industry leaders such as Genentech/Roche and the University of Adelaide focused on Ulcerative Colitis. With this funding, Microbiotica is poised to accelerate its groundbreaking research and development, aiming to transform therapies and improve patient outcomes in areas where effective solutions remain elusive. As the microbiome continues to emerge as a critical frontier in medicine, Microbiotica's innovative approaches and depth of expertise position it uniquely within the landscape of healthcare. The company is set to make significant strides in understanding and manipulating the microbiome, ultimately enhancing therapies for patients worldwide.
Microbiotica Announces $50 Million Series B Funding Round for Advancements in Microbiome Analysis and Therapeutics
Get the full Microbiotica company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Telepatia AI
Telepatia AI is a healthtech company on a mission to transform healthcare in Latin America and beyond. Born at Stanford and built by doctors for doctors, our platform introduces AI Healthcare Employees that work invisibly inside clinical workflows — transcribing consultations in real time, generating structured medical records, offering evidence-based decision support, and integrating seamlessly with any current health system — all without disrupting the physician’s flow. Already adopted by thousands of doctors and leading hospitals across the region, Telepatia has demonstrated measurable impact: reducing cognitive load, improving patient experience, and increasing adherence to clinical protocols. Our vision is bold: to turn scarcity into abundance by empowering healthcare professionals with scalable, trustworthy intelligence — and to pursue nothing less than the first Nobel Prize in Medicine for Latin America since 1984 with an AI Doctor.
$42.0M Series a
today
OneSoil
OneSoil transforms agricultural decisions from guesswork to data-driven precision. We help farmers and enterprises maximize profitability and sustainability through satellite intelligence and field-level insights. For Farmers & Agronomists: Our easy-to-use platform puts actionable data in your pocket. Scout fields efficiently with our mobile app, identify problem spots in real-time, and optimize input applications down to the hectare. For Enterprises: We deliver global agricultural intelligence at scale. Covering 59 countries with crop detection, yield forecasting, and supply chain monitoring - our data arrives 8 months ahead of official statistics, giving you the competitive edge that matters in commodity markets and strategic planning. The Same Technology, Two Markets Whether you're protecting your farm's bottom line or making billion-dollar decisions across global supply chains, OneSoil's satellite-derived insights, proprietary algorithms, and machine learning deliver precision agriculture that actually pays off. Quick to implement. Proven results. Built for real-world farming.
$1.2M Seed
today
Edvisor
Edvisor is the #1 Student Recruitment Software that helps international education companies streamline the way they sell education - whether they recruit students directly, through agencies or both. Supported by the biggest network of agencies, institutions and service providers, with more than 10K registered users across 42 countries and exclusive partnerships with the best associations and industry organizations.
$1.3M Pre-seed
today
Spoon Cereals
We find mornings just as hard as the next person, which is why we set out to make breakfast better for everyone...Better tasting, better for you and better for the planet. Our granolas are made with quality, good-for-you ingredients and baked in small batches, which means fresher granola and less waste.
$1.9M Seed
today
HyperLight
The information age relies on billions of devices converting signals between electricity and light waves. These integrated light circuits are the backbone of telecommunication infrastructures, data centers, sensors, and even secure quantum communications. Our devices set new benchmarks for performance, including extraordinary speed and efficiency, that will force industries to rethink and reimagine their current standards.
$80.0M Series c
today
Other recent Series b rounds
Companies that recently closed a Series b round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Silicon Quantum Computing Australia | Series b | $40.0M | today |
| 2 |  CuspAI | Series b | $400.0M | today |
| 3 |  Twenty United States | Series b | $100.0M | today |
| 4 |  Team Liquid United States | Series b | $35.0M | 1d ago |
| 5 |  Incredibuild Israel | Series b | $35.0M | 1d ago |